PCM
SPRB

Prelude Capital Management’s Spruce Biosciences SPRB Stock Holding History

Prelude Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-223
Closed -$75K – 2314
2021
Q4 		$75K Buy
+223
New +$66.4K ﹤0.01% 1757

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prelude Capital Management's SPRB Position: Q1 2022 in Review

Prelude Capital Management sold out of Spruce Biosciences (SPRB) in Q1 2022, closing a stake of 223 shares — an estimated $75K sold.

Prelude Capital Management first reported a position in SPRB in Q4 2021 and held it in 1 quarter. The position peaked at $75K in Q4 2021. 43 funds tracked by Wall St. Rank hold SPRB as of Q1 2022.

  • Prelude Capital Management reported no remaining Spruce Biosciences position as of Q1 2022 after selling out during the quarter.
  • Prelude Capital Management sold 223 Spruce Biosciences shares in Q1 2022, an estimated $75K.
  • Prelude Capital Management first reported a position in Spruce Biosciences in Q4 2021 and held it in 1 quarter.
  • Prelude Capital Management's Spruce Biosciences position peaked at $75K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2022.

Based on Prelude Capital Management's 13F filing for Q1 2022, filed 16 May 2022.